Fig. 3: Progression-free survival and duration of response. | British Journal of Cancer

Fig. 3: Progression-free survival and duration of response.

From: A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Fig. 3

a Overall and b by PD-L1 expression (tumour response analysis set). PD-L1 TC expression (high: ≥20%; low/negative: <20%) was determined at baseline. CI confidence interval, DoR duration of response, NC not calculable, PD-L1 programmed cell death ligand-1, PFS progression-free survival, TC tumour cell.

Back to article page